Commave Therap Drug Patent Portfolio
Commave Therap owns 1 orange book drug protected by 6 US patents Given below is the list of Commave Therap's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10584112 | Methylphenidate-prodrugs, processes of making and using the same | 09 Dec, 2037 | Active |
| US10584113 | Methylphenidate-prodrugs, processes of making and using the same | 09 Dec, 2037 | Active |
| US10759778 | Methylphenidate-prodrugs, processes of making and using the same | 09 Dec, 2037 | Active |
| US10858341 | Compositions comprising methylphenidate-prodrugs, processes of making and using the same | 09 Dec, 2037 | Active |
| US10954213 | Compositions comprising methylphenidate-prodrugs, processes of making and using the same | 09 Dec, 2037 | Active |
| US9079928 | Methylphenidate-oxoacid conjugates, processes of making and using the same | 27 Jul, 2032 | Active |
Latest Legal Activities on Commave Therap's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Commave Therap.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US9079928 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 31 Dec, 2023 | US10759778 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 31 Dec, 2023 | US10858341 |
| transaction for FDA Determination of Regulatory Review Period | 29 Nov, 2023 | US9079928 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Sep, 2023 | US10584112 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Sep, 2023 | US10584113 |
|
Email Notification
Critical
| 17 May, 2023 | US9079928 |
|
Electronic Review
Critical
| 17 May, 2023 | US9079928 |
| Second letter to regulating agency to determine regulatory review period | 16 May, 2023 | US9079928 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jan, 2023 | US9079928 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2022 | US9079928 |
| Initial letter Re: PTE Application to regulating agency | 27 Jan, 2022 | US9079928 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 Mar, 2021 | US10954213 |
|
Recordation of Patent Grant Mailed
Critical
| 23 Mar, 2021 | US10954213 |
|
Email Notification
Critical
| 05 Mar, 2021 | US10954213 |
Commave Therap's Family Patents
Commave Therap drugs have patent protection in a total of 28 countries. It's US patent count contributes only to 28.4% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Commave Therap Drug List
Given below is the complete list of Commave Therap's drugs and the patents protecting them.
1. Azstarys
Azstarys is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10584112 | Methylphenidate-prodrugs, processes of making and using the same |
09 Dec, 2037
(13 years from now)
| Active |
| US10584113 | Methylphenidate-prodrugs, processes of making and using the same |
09 Dec, 2037
(13 years from now)
| Active |
| US10759778 | Methylphenidate-prodrugs, processes of making and using the same |
09 Dec, 2037
(13 years from now)
| Active |
| US10858341 | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
09 Dec, 2037
(13 years from now)
| Active |
| US10954213 | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
09 Dec, 2037
(13 years from now)
| Active |
| US9079928 | Methylphenidate-oxoacid conjugates, processes of making and using the same |
27 Jul, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Azstarys's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List